Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.

Adult Aged Aged, 80 and over Allografts Cytarabine / administration & dosage Daunorubicin / administration & dosage Disease-Free Survival Female Follow-Up Studies Hematopoietic Stem Cell Transplantation Humans Leukemia, Myeloid, Acute / blood Male Middle Aged Neoplasm, Residual Survival Rate

Journal

Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469

Informations de publication

Date de publication:
04 10 2021
Historique:
received: 08 07 2021
accepted: 17 09 2021
revised: 07 09 2021
entrez: 5 10 2021
pubmed: 6 10 2021
medline: 1 2 2022
Statut: epublish

Résumé

To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available information achieving measurable residual disease (MRD) negativity (<10

Identifiants

DOI: 10.1038/s41408-021-00558-5 PMID: 34608129 PMC: PMC8490353
pubmed: 34608129
doi: 10.1038/s41408-021-00558-5
pii: 10.1038/s41408-021-00558-5
pmc: PMC8490353
doi:

Substances chimiques

CPX-351 0
Cytarabine 04079A1RDZ
Daunorubicin ZS7284E0ZP

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

164

Informations de copyright

© 2021. The Author(s).

Références

Blood. 2011 Feb 17;117(7):2137-45
pubmed: 21127174
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Ann Hematol. 2017 Dec;96(12):1993-2003
pubmed: 29090343
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
J Clin Oncol. 2007 Sep 20;25(27):4246-54
pubmed: 17724349
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
J Clin Oncol. 2015 Nov 1;33(31):3641-9
pubmed: 26304885
Leukemia. 2013 Oct;27(10):2068-72
pubmed: 23648670
Leukemia. 2021 Aug;35(8):2358-2370
pubmed: 33526859
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Blood Cancer J. 2020 Oct 6;10(10):96
pubmed: 33024084
Blood Adv. 2021 Mar 23;5(6):1719-1728
pubmed: 33724305
Int J Nanomedicine. 2019 May 23;14:3819-3830
pubmed: 31213803
Blood Adv. 2019 Oct 22;3(20):2911-2919
pubmed: 31648312
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2019 Feb;33(2):379-389
pubmed: 30555165
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Blood Adv. 2021 Jan 12;5(1):176-184
pubmed: 33570629
Blood. 2012 Apr 26;119(17):3890-9
pubmed: 22383796
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Am J Hematol. 2015 Mar;90(3):208-14
pubmed: 25421221

Auteurs

Christina Rautenberg (C)

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.

Friedrich Stölzel (F)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
ORCID: 0000-0003-0653-5332

Christoph Röllig (C)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.

Matthias Stelljes (M)

Department of Medicine A, University Hospital Münster, Münster, Germany.

Verena Gaidzik (V)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Michael Lauseker (M)

Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University, Munich, Germany.
ORCID: 0000-0002-6662-7127

Oliver Kriege (O)

Department of Medicine III, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.

Mareike Verbeek (M)

Department of Medicine III, Technical University of Munich, Munich, Germany.

Julia Marie Unglaub (JM)

Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

Felicitas Thol (F)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

Stefan W Krause (SW)

Department V for Internal Medicine, University Hospital Erlangen, Erlangen, Germany.
ORCID: 0000-0002-5259-4651

Mathias Hänel (M)

Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.

Charlotte Neuerburg (C)

Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.

Vladan Vucinic (V)

Leipzig: Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology, Leipzig, Germany.

Christian-Friedrich Jehn (CF)

Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Clinic St. Georg, Hamburg, Germany.

Julia Severmann (J)

Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany.

Maxi Wass (M)

Clinic and Policlinic for Internal Medicine IV, University Hospital Halle (Saale), Halle (Saale), Germany.

Lars Fransecky (L)

Departmenf for Internal Medicine II, University Schleswig-Holstein, Kiel, Germany.

Jens Chemnitz (J)

Gemeinschaftsklinikum Mittelrhein GGmbH, Koblenz, Germany.

Udo Holtick (U)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.

Kerstin Schäfer-Eckart (K)

Department of Internal Medicine V, Oncology and Hematology, Klinikum Nürnberg, Nürnberg, Germany.

Josephine Schröder (J)

Clinic for Heaematology and Stem Cell Transplantation HELIOS Clinic Berlin-Buch GmbH, Berlin, Germany.

Sabrina Kraus (S)

Division of Hematology and Oncology, Department of Internal Medicine II, University of Würzburg, Medical Center, Würzburg, Germany.

William Krüger (W)

Clinic and Policlinic for Internal Medicine C, Hematology and Oncology, University of Greifswald, Greifswald, Germany.

Ulrich Kaiser (U)

Department of Hematology and Oncology, St. Bernward Krankenhaus, Hildesheim, Germany.

Sebastian Scholl (S)

Department of Internal Medicine II, Hematology and Oncology, University Hospital Jena, Jena, Germany.

Kathrin Koch (K)

Department of Medicine III, Technical University of Munich, Munich, Germany.

Lea Henning (L)

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.

Guido Kobbe (G)

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.

Rainer Haas (R)

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.

Nael Alakel (N)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.

Maximilian-Alexander Röhnert (MA)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.

Katja Sockel (K)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.
ORCID: 0000-0003-1732-7299

Maher Hanoun (M)

Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany.

Uwe Platzbecker (U)

Leipzig: Department of Hematology and Cell Therapy, Medical Oncology, Hemostaseology, Leipzig, Germany.

Tobias A W Holderried (TAW)

Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.

Anke Morgner (A)

Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany.

Michael Heuser (M)

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
ORCID: 0000-0001-5318-9044

Tim Sauer (T)

Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

Katharina S Götze (KS)

Department of Medicine III, Technical University of Munich, Munich, Germany.

Eva Wagner-Drouet (E)

Department of Medicine III, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.

Konstanze Döhner (K)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Hartmut Döhner (H)

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.

Christoph Schliemann (C)

Department of Medicine A, University Hospital Münster, Münster, Germany.

Johannes Schetelig (J)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.

Martin Bornhäuser (M)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany.

Ulrich Germing (U)

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany.

Thomas Schroeder (T)

Department of Hematology, Oncology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine-University, Duesseldorf, Germany. Thomas.schroeder@uk-essen.de.
Department of Hematology and Stem Cell Transplantation, West German Cancer Center Essen, University Hospital Essen, Essen, Germany. Thomas.schroeder@uk-essen.de.
ORCID: 0000-0002-1653-7959

Jan Moritz Middeke (JM)

Medizinische Klinik und Poliklinik I, University Hospital Carl Gustav Carus Dresden, Technical University Dresden, Dresden, Germany. Janmoritz.middeke@ukdd.de.
ORCID: 0000-0003-3250-293X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Régions du corps › Transplants › Allogreffes › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Cytarabine › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Glucides › Hétérosides › Aminosides › Anthracyclines › Daunorubicine › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Real-world experience of CPX-351 as first-line...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Real-world experience of CPX-351 as first-line...